Neoral® in the treatment of psoriasis: Consensus treatment guidelines

Journal of Cutaneous Medicine and Surgery

Volumn 1, Issue 4, 1997, Pages 209-215

  Ho, Vincent ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG SAFETY; HUMAN; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSORIASIS;

EID: 0031391638     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347549700100406     Document Type: Article

References (7)

1. Hellgren L. Psoriasis: the prevalence in sex, age and occupational groups in total population in Sweden: morphology, inheritance and association with other skin and rheumatic diseases. Stockholm: Almquist & Wiskell, 1967:106-110.
2. Lomholt GZ. Psoriasis affects quality of life. Haut-Geschlechtskrankh 1965; 19:223-227.
3. Ptechcinski RJ, Venkataromanan R, Buckart CJ. Clinical pharmacokinetics of cyclosporin. Clin Pharm 1986; 11:107-132.
4. Grevel J. Absorption of cyclosporine A after oral dosing. Transplant Proc 1986; 18:9-15.
5. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28:454-459.
6. Koo J. Cyclosporine in dermatology. Fears and opportunities. Arch Dermatol 1995; 131:842-845.
7. Berth-Jones J, Voorhees JJ. Consensus conference on cyclosporine A microemulsion for psoriasis. Br J Dermatol 1996; 5:775-777.